Studies indicate that glutathione deficiency is linked to higher oxidative stress, which contributes to aging and chronic diseases (5)
This is consistent with the fact that this class of drugs produces significant appetite suppression in response to central and peripheral GLP-1 R activation and has been actively used in the treatment of T2DM, obesity, and overweight ( Our study identified a potential risk of dehydration with dulaglutide, liraglutide, semaglutide, and tirzepatide, semaglutide emerged as having the highest risk of various fluid reductions (Supplementary Table S2)
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
For a copy of the Safety Data Sheet (SDS) or to report suspected adverse drug events, contact Pegasus Laboratories at 1-800-874-9764
Other common side effects associated with GLP-1s include constipation, loss of muscle mass or bone density, and, less commonly, abdominal pain, according to the Obesity Action Coalition
[93] In an open trial of 32 patients with treatment refractory brain tumors, intravenous infusion of selenium (1000 mcg/day for 4-8 weeks) was associated with a slight to definite improvement in all participants
